Equities

Avant Technologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AVAI:QBB

Avant Technologies Inc

Actions
  • Price (USD)0.4318
  • Today's Change0.030 / 7.39%
  • Shares traded21.78k
  • 1 Year change-31.45%
  • Beta0.9098
Data delayed at least 15 minutes, as of Feb 13 2026 20:34 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Avai Bio, Inc., formerly Avant Technologies, Inc., is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing cell-based therapies. The Company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an a-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. It has secured Joint Venture and Licensing Agreements to develop both cell lines. Its diabetes program is focused on developing an insulin-producing cell line, then encapsulating those cells inside using SGAustria's Cell-in-a-Box technology to create a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes. The Company is partnering with biotech firms, universities, scientists, and clinicians to uncover solutions for diverse healthcare challenges.

  • Revenue in USD (TTM)0.00
  • Net income in USD-928.84k
  • Incorporated2017
  • Employees0.00
  • Location
    Avant Technologies Incc/o Eastbiz.com, Inc, 5348 Vegas DriveLAS VEGAS 89108United StatesUSA
  • Phone+1 (702) 509-1747
  • Fax+1 (702) 872-2060
  • Websitehttps://avaibio.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Moatable Inc (ADR)75.16m-2.26m53.36m610.00------0.71-0.1256-0.12564.17--1.05--16.99123,216.40-5.37-19.74-6.26-28.4674.5577.77-5.10-65.01----0.2319--21.87-28.9278.80---4.02--
Upexi Inc20.69m54.69m53.63m59.00--0.21480.96912.59-3.60-3.600.69513.580.09443.3538.12350,755.6024.95-24.4430.05-35.1578.3857.00264.27-44.463.39--0.4857---39.1916.3645.85---27.45--
Gamehaus Holdings Inc-100.00bn-100.00bn54.11m153.00--2.18----------0.4641------------------------2.45-------18.72---51.97------
Metalpha Technology Holding Ltd44.57m15.89m54.90m25.003.381.493.421.230.41110.41111.160.93530.2115--22.241,782,690.007.54-4.0559.49-23.1447.80--35.66-23.97--231.750.0058--165.86424.29531.99------
Skillz Inc92.26m-77.50m57.26m323.00--0.456--0.6207-4.77-4.775.708.310.2638--9.44285,622.30-22.16-36.56-26.27-41.2186.1591.37-84.01-82.22---18.300.4999---38.94-4.9853.84---4.89--
MoneyHero Ltd69.18m-23.89m57.36m286.00--1.49--0.8292-0.8578-0.85782.560.87740.829--2.05241,897.70-28.63---49.80--51.11---34.54-----2.220.0287---1.44--78.11------
Phonex Holdings Inc74.17m-13.62m57.64m19.00--40.01--0.7772-0.5616-0.56162.750.04254.1112.95249.49---75.55-46.80-135.15-67.782.1110.44-18.37-12.660.43-2.390.8233--10.61113.08-231.42--17.69--
PLAYSTUDIOS Inc247.48m-37.36m58.85m556.00--0.246327.910.2378-0.2987-0.29871.981.890.786--8.27445,102.50-11.87-3.03-13.35-3.4675.0171.06-15.10-2.92----0.00---6.903.87-47.92---2.22--
Sound Group Inc - ADR356.91m4.62m59.26m563.0015.831.49--0.1660.90010.900169.509.564.37--2,295.63633,934.604.09-12.177.93-26.9928.5028.690.9365-3.41----0.00---1.9311.4745.06---16.15--
Avai Bio Inc0.00-928.84k59.70m0.00---------0.0068-0.00680.00-0.01670.00-------450.46-187.70-----------167.86------------46.34------
IZEA Worldwide Inc36.18m-3.41m61.48m110.00--1.23--1.70-0.2016-0.20162.062.930.5742--7.32328,877.20-5.42-12.89-6.60-16.1345.3044.21-9.43-27.50---437.270.0004---0.921213.61-156.52--3.46--
Beachbody Company Inc282.57m-42.64m62.80m355.00--2.54--0.2223-6.22-6.2240.753.481.525.44179.81795,957.80-22.93-34.33-65.50-67.0871.9563.37-15.09-19.800.5289-2.130.4872---20.55-11.1453.07---28.20--
Grove Collaborative Holdings Inc180.81m-24.27m62.91m339.00------0.3479-0.6349-0.63494.690.20842.263.78--533,356.90-28.49---49.09--53.5049.99-12.59-23.920.5284--0.4652---21.54-2.6936.36---31.46--
Gaia Inc97.89m-4.71m64.23m104.00--0.94934.750.6562-0.1916-0.1944.003.440.6734--18.37941,240.40-3.62-1.58-5.74-2.0687.2386.41-5.38-2.50----0.0529--12.3610.859.81---5.85--
SUPA Consolidated Inc0.00-49.63k64.68m0.00117.0515.53551.28--0.00190.00190.000.01430.00-------1.86-60.57-2.92-177.44-----------2.570.1288------128.42------
Data as of Feb 13 2026. Currency figures normalised to Avant Technologies Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.